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With the development of several new anti-thrombotic agents for stroke prevention in patients with atrial fibrillation (AF), the role of warfarin in the 
current era would have to be better characterized. We aimed to determine the safety and efficacy estimates reported in contemporary trials using 
warfarin in comparison to the prior trials.
Methods: Randomized controlled trials (RCTs) comparing warfarin to an alternative anti-thrombotic strategy for stroke prevention in AF, published 
between 2000 - 2011, were utilized. RCTs conducted between 1989 - 2000, listed in the prior meta-analysis (published in 1999 by Hart et al) were 
retrieved and served as the comparison group.
Results: There has been a reduction in the rate of thromboembolic events in the current era (1.66%/year) in comparison to the earlier trials 
(2.09%/year). Although there was a significant heterogeneity in the definition of the target therapeutic range in the earlier trials, the target INR range 
was uniformly 2.0 - 3.0 in the contemporary trials. Moreover, there was a significant improvement in the proportion of time spent in therapeutic 
range in the contemporary trials.
Conclusions: There has been a reduction in the thromboembolic event rate in the contemporary era, compared to the rates reported in earlier 
RCTs. This may be attributable to an improved anticoagulation quality in the current era. These rates should form the framework for development of 
future superiority and non inferiority clinical trials in this area. 
Trial/Year Patient-years Target INR
% Time in therapeutic 
range
Strokes/ TIA/ non-CNS 
embolism
All-cause mortality Major bleeding
PRIOR META ANALYSIS (Hart et al, 1999)
AFASAK/ 1989 413 2.8 - 4.2 42.0 9 (2.18) - -
BAATAF/ 1990 487 1.5 - 2.7 83.0 2 (0.41) 11 (2.26) 3 (0.62)
SPAF/ 1991 263 2.0 - 4.5 71.0 8 (3.04) 6 (2.31) 4 (1.54)
CAFA/ 1991 237 2.0 - 3.0 43.7 8 (3.38) - 5 (2.50)
SPINAF/ 1992 440 1.4 - 2.8 56.0 5 (1.14) 15 (3.30) 6 (1.36)
EAFT/ 1993 507 2.5 - 4.0 59.0 20 (3.95) 41 (8.09) 13 (2.56)
Pooled estimate (95% CI) 2347 2.09 (0.89 - 3.30) 3.82 (1.60 - 6.05) -*
CURRENT META ANALYSIS
SPORTIF III/ 2003 2440 2.0 - 3.0 66.0 56 (2.30) 79 (3.20) 41 (1.80)
SPORTIF V / 2005 3212 2.0 - 3.0 68.0 37 (1.20) 123 (3.80) 84 (3.10)
ACTIVE-W / 2006 4242 2.0 - 3.0 63.8 59 (1.40) 158 (3.76) 93 (2.21)
BAFTA/ 2007 1318 2.0 - 3.0 67.0 22 (1.68) 107 (8.00) 25 (1.89)
AMADEUS/ 2008 2159 2.0 - 3.0 63.0 27 (1.30)
61
(2.90)
29 (1.40)
RE-LY/ 2009 12044 2.0 - 3.0 64.0 199 (1.69) 487 (4.13) 397 (3.36)
ROCKET-AF/ 2011 14028 2.0 - 3.0 55.0 243 (2.20) 250 (2.21) 386 (3.40)
ARISTOTLE/ 2011 16346 2.0 - 3.0 62.2 265 (1.60) 669 (3.94) 462 (3.09)
Pooled estimate (95% CI) 55789 1.66 (1.41 - 1.91) 3.83 (3.07 - 4.58) -*
Table 1: Characteristics, individual outcomes and pooled event rates in atrial fibrillation patients on warfarin for stroke prevention reported in prior 
studies in comparison to contemporary studies.
* Not pooled due to heterogeneity in definition of major bleeding across trials. 
